Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Phase 2

Active, not recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-23

Last Posted Date: 2025-01-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 80

Registration Number: NCT03505762

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Tolerance by Engaging Antigen During Cellular Homeostasis

Phase 1

Active, not recruiting

Conditions: Renal Transplantation
Renal Transplant Recipient
Kidney Transplantation

Interventions: Biological: Donor-derived Mesenchymal Stromal Cells
Drug: alemtuzumab
Drug: belatacept
Drug: sirolimus
Drug: mycophenolate mofetil
Drug: mycophenolate acid
Drug: prednisone

First Posted Date: 2018-04-20

Last Posted Date: 2024-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT03504241

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States

CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Not Applicable

Terminated

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Cyclophosphamide
Drug: Methylprednisolone
Drug: Prednisone
Drug: Mycophenolate Mofetil

First Posted Date: 2018-04-10

Last Posted Date: 2021-07-21

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 49

Registration Number: NCT03492255

Locations: 🇧🇷
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia in Remission
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-04

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03488225

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma
Non-Hodgkin Lymphoma

Interventions: Drug: Glofitamab
Drug: Obinutuzumab (G)
Drug: Rituximab (R)
Drug: Tocilizumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Polatuzumab vedotin
Drug: Prednisone

First Posted Date: 2018-03-16

Last Posted Date: 2024-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 172

Registration Number: NCT03467373

Locations: 🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
🇺🇸
University of Alabama Medical Center, Birmingham, Alabama, United States
🇺🇸
Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States

and more 21 locations

The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.

Not Applicable

Terminated

Conditions: Idiopathic Membranous Nephropathy

Interventions: Drug: Prednisone
Drug: MP and CTX

First Posted Date: 2018-03-15

Last Posted Date: 2022-02-17

Lead Sponsor: Wenhu Liu

Target Recruit Count: 6

Registration Number: NCT03466801

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor(GIST)

Interventions: Drug: Prednisone

First Posted Date: 2018-02-22

Last Posted Date: 2020-01-07

Lead Sponsor: Asan Medical Center

Target Recruit Count: 29

Registration Number: NCT03440515

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Vamorolone
Other: Placebo
Drug: Prednisone

First Posted Date: 2018-02-20

Last Posted Date: 2023-03-09

Lead Sponsor: ReveraGen BioPharma, Inc.

Target Recruit Count: 121

Registration Number: NCT03439670

Locations: 🇨🇦
Montreal Children's Hospital, Montréal, Quebec, Canada
🇧🇪
Ghent University Hospital, Ghent, Belgium
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 30 locations

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Abiraterone Acetate
Radiation: Stereotactic Body Radiation Therapy
Procedure: Extended Pelvic lymphadenectomy
Drug: Prednisone
Procedure: Radical Prostatectomy
Drug: GnRH agonist/antagonist

First Posted Date: 2018-02-19

Last Posted Date: 2024-11-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 102

Registration Number: NCT03436654

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Phase 4

Conditions: Multiple Sclerosis

Interventions: Drug: Plegridy
Drug: Prednisone
Drug: Tylenol Pill

First Posted Date: 2018-02-07

Last Posted Date: 2019-08-15

Lead Sponsor: Holy Name Medical Center, Inc.

Target Recruit Count: 50

Registration Number: NCT03424733

Locations: 🇺🇸
Holy Name Medical Center, Teaneck, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy